NAD says hair supplement claims stretch accuracy
The National Advertising Division advises Irish firm Lifes2Good Natural Healthcare to modify advertising for its Viviscal dietary supplement - promoted to nourish hair follicles with vitamin C, silica and glycosaminoglycans - to assure it is gender neutral. The marketing in question comprised radio, print and Internet ads, including one that featured the testimonial of an actress and "health enthusiast" as well as the statement that one in three women will be affected by thinning hair during their lifetime, according to the division of the Council of Better Business Bureaus. NAD determined that because the studies supporting the efficacy of the product were conducted on men only, the advertiser should revise its ads to avoid indicating the product has been shown to work in women. NAD also recommended the firm discontinue the claim the product is "doctor recommended." Lifes2Good substantiated the claim the product is "Recommended by top celebrities and models." Lifes2Good said it disagreed with NAD's decision regarding the gender focus of its ads, but the Galway, Ireland-based firm agreed to comply with the recommendations
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
A new chapter that will be published in the European Pharmacopoeia soon is expected to provide a comprehensive framework for the production and quality control of cell-based preparations. Meanwhile, an existing chapter has been revised to facilitate the implementation of rapid microbiological testing methods.
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.